Brain-derived Tau: A Novel Plasma Biomarker for AD-specific Neurodegeneration and Clinical Outcome Prediction after sTBI and AIS
App Note
BD-Tau is a promising plasma biomarker for AD-specific neurodegeneration and brain injury, offering better diagnostic accuracy than traditional t-Tau. It tracks well with amyloid pathophysiology and helps predict cognitive decline in AD. BD-Tau is also valuable for monitoring recovery after sTBI and predicting outcomes after AIS. Read this app note to see how when measured using Simoa® assays, BD-Tau provides ultra-sensitive and reliable detection for improved clinical decision-making and patient care.
Fill out the form to download the app note